uid	pubdate	authors	title	fulljournalname	elocationid
40977462	2025 Sep 22	Liu SY, Lin LT, Chang CH, Chen YJ	Liposomal (188)Rhenium Plus Macrophage Depletion Enhances Anti-PD-L1 Efficacy and B Cell Infiltration Against Lung Metastatic Cancer.	Cancer science	doi: 10.1111/cas.70206
40976819	2025 Sep 21	ang M	Histone lactylation in gastrointestinal cancers: developing immunotherapeutic drugs targeting epigenetics.	Archives of pharmacal research	doi: 10.1007/s12272-025-01570-0
40976783	2025 Sep 22	Gao P, Zuo C, Yuan W, Cai J, Chai X, Gong R, Yu J, Yao L, Su W, Liu Z, Lin S, Wang Y, Cai M, Ma L, Li Q, Zhou P	Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer.	Signal transduction and targeted therapy	doi: 10.1038/s41392-025-02390-w
40976299	2025 Sep 19	asemi K	C-C motif glycoprotein ligand 5 (CCL5) and its GPCR CCR5: Macromolecular game-changers in cancer biology.	International journal of biological macromolecules	doi: 10.1016/j.ijbiomac.2025.147737
40976049	2025 Sep 20	Zhu J, Zhang L, Hui X, Shang L, Ma J, Zhang Q	SMC4 promotes immune evasion by inhibiting endogenous interferon signaling and upregulating PD-L1 expression in triple negative breast cancer.	International immunopharmacology	doi: 10.1016/j.intimp.2025.115580
40975978	2025 Sep 20	Jing D, Chen B, Liang R, Li F, Zhao B, Pu F, Wu W	GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.	Neoplasia (New York, N.Y.)	doi: 10.1016/j.neo.2025.101232
40975903	2025 Sep 20	Ferreira DL, Biojout T, Bazille C, Guyot M, Malandain L, Charrier L, Toutain J, Peres E, Valable S, Madelaine J, Levallet J, Levallet G, Bergot E	Amphiregulin reflects brain metastasis progression and leads to PD-L1 expression in non-small cell lung cancer cells.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	doi: 10.1016/j.biopha.2025.118600
40975760	2025 Sep 20	Xian J, Pan X, Kang Y, Zheng L, Yin X, Zhang M, Wei Y, Tan J, Zhang M, Nie L, Chen X, Zeng H, Zhou Q, Chen N	Fumarate activates the IL-6/JAK/STAT3 pathway by inhibiting KDM4C-mediated H3K36me3 demethylation in FH-knockdown renal cancer cells.	British journal of cancer	doi: 10.1038/s41416-025-03195-y
40975344	2025 Sep 18	Xu Y, Qian T, Pan H, Gu Y, Xu M, Bai C, Chen W	Akkermansia muciniphila-derived outer membrane protein Amuc_1100 promotes acetylation of RING Finger Protein 181 promoter and mediates Autophagy Related 7 ubiquitination to activate CD8(+) T cells in lung adenocarcinoma.	International journal of biological macromolecules	doi: 10.1016/j.ijbiomac.2025.147773
40974690	2025 Sep 19	Yuan X, Li C, Zhang X, Feng X	Recurrent pregnancy loss: Crosstalk between immune cells, decidual cells, and cellular autophagy.	Reproductive biology	doi: 10.1016/j.repbio.2025.101083
40974651	2025 Sep 15	Nishibori S, Takeda Y, Igase M, Mizuno T	Engineering an Fc-inert feline IgG1 by targeted mutations: Application to anti-PD-1 antibody development.	Veterinary immunology and immunopathology	doi: 10.1016/j.vetimm.2025.111000
40974370	2025 Sep 20	Zhu J, Huang L, Bi S, Kong W, Feng W, Li Y, Xie Z, Shan P, Zhu S	Vitiligo Signature-Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	doi: 10.1002/advs.202503979
40974147	2025 Sep 20	Cheng X, Jiang S, Peng X, Yang P, Zhang S, Xu C, Gao X, Fan S, Liu H, Zhuang J, Chen X, Liang N, Lin B, Lu Q, Chen M, Xiao Y, Zhu Z, Wang R, Hu K, Wu C	Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept.	Journal of the American Chemical Society	doi: 10.1021/jacs.5c11292
40973957	2025 Sep 19	Zhou R, Zhu YJ, He YH, Lin JJ, Zhang ZX, Zhao WJ, Ma HC, Chang XS, Chen YD, Li WZ, Chen X, Chai XS, Zhang HB	The association between acupuncture and response to immune checkpoint inhibitors in non-small cell lung cancer.	Chinese medicine	doi: 10.1186/s13020-025-01148-4
40973860	2025 Sep 19	Ji Y, Cui K, Zhang J, Wang J, Dai Z, Cui Y, Ge H, Zheng J, Yu D	ASO Visual Abstract: Noninvasive Prediction of PD-L1 Expression in LA-NSCLC by 18F-FDG PET/CT-Based Metabolic Habitats: A Multicenter Radiomic and Biological Study.	Annals of surgical oncology	doi: 10.1245/s10434-025-18362-x
40973222	2025 Sep 18	Chat V, Fletez-Brant K, Srivastava M, Nabet B, Mellman I, McCarthy MI, Hammer C	Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer.	Journal for immunotherapy of cancer	pii: e011565. doi: 10.1136/jitc-2025-011565
40973067	2025 Jan-Dec	Yang M, Qiu D, Huang M, Yu S, Xuan F	Adverse Events of Immune Checkpoint Inhibitors in Cancer Patients with Comorbid Diabetes: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System Database (2011-2025).	Cancer control : journal of the Moffitt Cancer Center	doi: 10.1177/10732748251381428
40973032	2025 Sep 17	Rimel BJ, Pujade-Lauraine E, Moore K, Pfisterer J, Han S, Cibula D, Reyners A, Redondo A, Papadimitriou C, Eitan R, Pignata S, Glasspool R, Mirza MR, Bodnar L, Duska L, Provencher D, Phaëton R, Bains M, Coskuncay E, Hardy-Bessard AC	Phase 3 Clinical Trials Evaluating Poly(ADP-Ribose) Polymerase Inhibition Plus Immunotherapy for First-Line Treatment of Advanced Ovarian Cancer.	The oncologist	pii: oyaf270. doi: 10.1093/oncolo/oyaf270
40972832	2025 Sep 17	Li Q, Deng MS, Wang RT, Luo H, Luo YY, Zhang DD, Chen KJ, Cao XF, Yang GM, Zhao TM, Xu B, Xu CX, Wang JM	Corrigendum to "PD-L1 upregulation promotes drug-induced pulmonary fibrosis by inhibiting vimentin degradation" [Pharmacol. Res. (2023) 106636 / PMID: 36586643].	Pharmacological research	doi: 10.1016/j.phrs.2025.107956
40972824	2025 Sep 17	Miao Z, Xu A, Shen G, Tang S, Luo J, Yang J, Chen Z, Pu J, Yang T	Fluorinated albumin nanocages dually target CAFs and tumor cells to potentiate bladder cancer chemoimmunotherapy.	Journal of controlled release : official journal of the Controlled Release Society	doi: 10.1016/j.jconrel.2025.114246
40972397	2025 Sep 18	Lo YL, Lin HC, Lee Y, Chuang HY, Chou TF	TME-responsive nanoparticles co-targeting VCP, NETs, and dual immune checkpoints for immune revitalization in EGFR/PD-L1/CTLA-4-driven colorectal cancer.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	doi: 10.1016/j.biopha.2025.118565
40972100	2025	Demirkol Ş, Zor DS, Uzunoğlu MS, Uzunoğlu AS, Dülger O, Hakan MT, Horozoğlu C, Turna A, Farooqi AA, Yaylım İ	Possible Associations between PD1/PDL1 Gene Variants, Gene Expression, and Protein Expression and Clinical Outcome of Non-Small-Cell Lung Cancer.	Critical reviews in eukaryotic gene expression	doi: 10.1615/CritRevEukaryotGeneExpr.2025059626
40972018	2025 Sep 16	Wittling MC, Bennett FJ, Warren EAK, Oppat KM, Wyatt MM, Hammons JN, Liu Y, Maithel SK, Paulos CM, Lesinski GB	Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma.	Journal of immunology (Baltimore, Md. : 1950)	pii: vkaf242. doi: 10.1093/jimmun/vkaf242
40971540	2025 Sep	Peng H, Yang P, Wang X, Zhao X, Li J, Gong Z, Zhang D, Wang Z	Unraveling the role of PREX2 mutations as a biomarker for immunotherapy response in colorectal cancer.	Cancer biomarkers : section A of Disease markers	doi: 10.1177/18758592251380454
40970928	2025 Sep 19	Wang X, Zhang Y, Li A, Zhou C, Xu S, Gu Z, Wang W, Nan P, Tao R	STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer.	Journal of gastroenterology	doi: 10.1007/s00535-025-02291-3
40970869	2025 Sep 19	Bekheet F, Ashland M, Reyes R, Dorigo O, Karam A, Chen CT	Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.	Immunotherapy	doi: 10.1080/1750743X.2025.2561398
40970797	2025 Sep	Callow BW, Luker GD	(68)Ga-NK224 PET/CT Enables Noninvasive Assessment of PD-L1 Expression and Tumor Heterogeneity.	Radiology. Imaging cancer	doi: 10.1148/rycan.259019
40970674	2025 Sep 19	Bai X, Wang H, Guo Q	Mechanisms of T cell-mediated immune evasion in cervical cancer: a comprehensive bibliometric analysis and future research directions.	Immunological medicine	doi: 10.1080/25785826.2025.2560214
40970356	2025 Nov	Lin YX, Liu H, Liao WC, Wang YC, Zhang BC, Wan SW, Chen CC, Chang CP	Senescence‑associated IL‑33 secretion undermines sorafenib efficacy in hepatocellular carcinoma via immune evasion.	Oncology reports	pii: 154. doi: 10.3892/or.2025.8987
40970322	2025 Nov	Ko D, Lee Y, Yoon J, Choi EK, Jang D, Kim S	Cooperation between ZEB2 and SP1 upregulates PD‑L1 and CCL2 to promote the immunosuppressive activity of tumor cells.	International journal of oncology	pii: 95. doi: 10.3892/ijo.2025.5801
40969813	2025	Huang J, Wang B, Wu B	The efficacy of low-dose anlotinib as a first-line treatment for frail patients with lung adenocarcinoma and its bridging significance for subsequent treatment: case report.	Frontiers in medicine	doi: 10.3389/fmed.2025.1659090
40969680	2025 Oct	Oresti S, Salomone F, Nuccio A, Ogliari FR, Riva ST, Mollica L, Bulotta A, Viganò MG, Venanzi FM, Passaretti F, Papotto L, Di Lello A, Ferrara M, Foggetti G, Damiano G, Servetto A, Califano R, Di Maio M, Ricciuti B, Cortellini A, Reck M, Cinquini M, Torri V, Viscardi G, Ferrara R	Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis.	EClinicalMedicine	doi: 10.1016/j.eclinm.2025.103482
40968606	2025 Sep 19	Jun HR, Lee JY, Lee C, Chun SM	Tumor-Type-Specific TMB Cutoffs for Improved ICI Outcome Prediction: Large-Scale Analysis with Real-World Targeted NGS Data.	Cancer research and treatment	doi: 10.4143/crt.2025.860
40968169	2025 Sep 18	Lesniak J, Schick M, Kunzke T, Pollastri F, Vigueras-Guillén JP, Hessel H, Haneder S, Sontakke P, DaCosta K, Alleze R, Zimmermann J, Kapil A, Brieu N, Shumilov A, Sade H, Barrett JC, Schmidt G, Stewart R	Enhanced patient selection with quantitative continuous scoring of PD-L1 expression for IO treatment in metastatic NSCLC.	NPJ precision oncology	doi: 10.1038/s41698-025-01107-0
40966845	2025 Sep 17	Zhou X, Zhang J, Lou Y, Li W, Xu Z, Zhang H, Li T	Immune and HPV landscape in oral multiple primary cancers compared to single primary cancer.	Oral oncology	doi: 10.1016/j.oraloncology.2025.107646
40966304	2025 Sep 18	Ma X, Liu Y, Chen Y, Wang J, Zhang F, Liang W, Zhang P, Zhou Y, Miao B, Fei S, Yamamoto M, Tsukamoto T, Nomura S, Li L, Wang J	BFAR promotes neutrophil infiltration and immunosuppressive reprogramming through the PRP19-YBX1 axis to induce immune evasion in gastric cancer.	Cancer immunology research	doi: 10.1158/2326-6066.CIR-24-1011
40965679	2025 Sep 18	Walter J, Nestle U, Weykamp F	[Neoadjuvant PD-1 and PD-L1 block with chemotherapy in borderline resectable and unresectable stage III NSCLC: paradigm shift or evidence-poor hype?].	Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]	doi: 10.1007/s00066-025-02457-1
40965079	2025 Sep 18	Wang J, Meng L, Meng F, Zhang T, Cheng G, Chen X, Liu Y	Natural Killer Cell-Mimicking Hypoxia-Responsive Nanomedicines for Tumor-Specific Suppression and Immune Regulation.	Small (Weinheim an der Bergstrasse, Germany)	doi: 10.1002/smll.202505680
40964496	2025	Dai X, Feng X, Li J, Peng F	SMARCA2 Deficiency While Preserving SMARCA4 in Lung Adenocarcinoma Combined with Abnormal β-Catenin Expression.	Cancer management and research	doi: 10.2147/CMAR.S533790
40963868	2025	Hua Y, Liu Y, Liu Y, Tian X, Zhang X, You J, Yin F	Bibliometric analysis of immunotherapy for esophageal cancer: 2004-2024.	Frontiers in oncology	doi: 10.3389/fonc.2025.1565132
40963634	2025	Peng H, Li B, Cui J, Sun G, Wang Q, Zhu Y, Wang S, Tu H, Wu X, Ye Z	Soluble immune checkpoint factors reveal high-risk osteosarcoma subtypes and enable early metastasis prediction.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1651051
40963630	2025	Wang T, Sun J, Wang L, Lin Y, Wu Z, Jia Q, Zhang S, An J, Ma X, Wu Q, Su Z, Wang H	Correction: Therapeutic potential of isochlorogenic acid A from Taraxacum officinale in improving immune response and enhancing the efficacy of PD-1/PD-L1 blockade in triple-negative breast cancer.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1672972
40963620	2025	Wen H, Zheng S, Zhu X, Wang L, Chen D	Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1643533
40963614	2025	Saddozai UAK, Lu Z, Dong S, Khawar MB, Fan Z, Cai L, Guo X, Akbar MU, Khattak S, Sun H, Wang Y	Prognostic value of metal-based ferroptosis and cuproptosis genes and score in lower grade gliomas.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1608077
40963599	2025	Sun P, Song D, Ma N, Hou S, Liu L, Gao J, Tian Y	Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of diffuse pleural mesothelioma: a systematic review and meta-analysis.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1578746
40963363	2025 Sep	Kuo YC, Cheng WC, Chen HY, Chien CR, Tu CY, Chen HJ	Real-World Evidence That Non-Smokers With High PD-L1 Non-Squamous NSCLC Have Poorer Outcomes With Immune Checkpoint Inhibitors.	Thoracic cancer	doi: 10.1111/1759-7714.70167
40963291	2025 Sep 17	ey C	Characterizing pulmonary adverse events associated with the immune checkpoint inhibitor avelumab: a FAERS-based pharmacovigilance study from 2013 to 2024.	Journal of chemotherapy (Florence, Italy)	doi: 10.1080/1120009X.2025.2561969
40963050	2025 Sep 17	Ji L, Chen X, Lyu H, Song G, Xiao M, Li Q, Wang J, Fan Y, Luo Y, Li Q, Chen S, Ma F, Xu B, Zhang P	Pathological complete response and survival outcomes in single hormone receptor-positive/HER2-negative breast cancer after neoadjuvant chemotherapy and its intrinsic biological features and immune landscape.	Breast cancer research and treatment	doi: 10.1007/s10549-025-07822-3
40962941	2025 Sep 17	Idris F, Ooi JSG, Ting DHR, Tan ETX, Wan C, Benke PI, Marzinek JK, Copping JM, Li QH, Ng LY, Lim SY, Walsh I, Allison JR, Bond PJ, Torta F, Nguyen-Khuong T, Chan KR, Alonso S	Glycans on non-structural protein 1 prevent premature T-cell mediated dengue virus clearance.	EMBO molecular medicine	doi: 10.1038/s44321-025-00311-6
40962725	2025 Sept 25	Zhao JY, Yuan GM, Li PY, Wang XM, Liu ZX, Xu Y, Guo YM, Li Y	[Effects of acupuncture on the efferocytosis pathway of Mer receptor tyrosine kinase in mice with adjuvant arthritis].	Zhen ci yan jiu = Acupuncture research	doi: 10.13702/j.1000-0607.20240585
40962068	2025 Sep 15	Majchrzak A, Niedźwiedzka-Rystwej P, Bębnowska D, Aksak-Wąs B, Karasińska-Cieślak M, Cembrowska-Lech D, Skonieczna-Żydecka K, Mielczak K, Urbańska A, Hrynkiewicz R, Lewandowski F, Parczewski M	Immune checkpoint molecules as predictive markers of COVID-19 severity: A comprehensive univariable and multivariable analysis.	Immunology letters	doi: 10.1016/j.imlet.2025.107089
40962058	2025 Sep 15	Zhou J, Nie H, Liu C, Ding L, Zheng T, Du L, Yu Y, Hong Y, Yang C, Zhao Q, Zhang M, Wang H, Wang F	USP52 inhibits cell ferroptosis via Hippo/YAP pathway and blocks immunotherapy in colorectal cancer.	The Journal of biological chemistry	doi: 10.1016/j.jbc.2025.110725
40961974	2025 Sep	Tanaka T, Tamiya M, Miyazaki A, Komura K, Futamura S, Kawamura T, Kunimasa K, Inoue T, Nishino K	Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel Therapy in Patients With Genetic Alterations in Non-Small Cell Lung Cancer.	Thoracic cancer	doi: 10.1111/1759-7714.70162
40961907	2025 Sep 16	Ding Y, Zhang H, Wang X, Tan J, Wang M, Chen Y, Safia IH, Zhu G, Zhang X, Liu Y	Targeting lysosomal protease CTSL promotes anti-tumor immunity and sensitizes HNSCC to PD-1 blockade by stabilizing PDK1 and activating Akt-PD-L1 axis.	Neoplasia (New York, N.Y.)	doi: 10.1016/j.neo.2025.101228
40961811	2025 Sep 12	Shiraishi Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, Morinaga R, Inoue H, Toi Y, Yamada T, Yamaguchi M, Kashiwabara K, Tobino K, Ishii H, Sakata Y, Inaba M, Nakashima K, Chibana K, Fukui T, Izumi M, Saito R, Ishii H, Omori S, Ogusu S, Furuyama K, Miura S, Harada T, Okamoto I	Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115779
40961752	2025 Sep 16	Yan H, Wang Y, Zhu M, Sun D, Li H, Chen L	Overcoming resistance to PD-1 inhibitors: the synergistic anti-tumor effect with inflammatory factors.	International immunopharmacology	doi: 10.1016/j.intimp.2025.115555
40961372	2025 Jul 18	Goodin DA, Daunke T, Beckinger S, Krüger S, Röcken C, Sebens S, Frieboes HB	Synergistic Effect of Anti-PD-L1 Treatment and CD8+ T-Cell Activating Nanotherapy in Pancreatic Ductal Adenocarcinoma Evaluated via 3D Mathematical Modeling.	Journal of immunotherapy (Hagerstown, Md. : 1997)	doi: 10.1097/CJI.0000000000000572
40961324	2025 Sep 17	Raush E, Totrov M, Hoop CL, Knowlan KM, Bianchi R, Tarasova NI	Novel GPU Engines for Virtual Screening of Giga-Sized Libraries Identify Inhibitors of Challenging Targets.	Journal of chemical information and modeling	doi: 10.1021/acs.jcim.5c01335
40960909	2025 Sep 30	Sun L, Hu J, Wang J, Zhu X, Yan Y, Wan S, Yu H, Jiang G, Zhang L, Hu H, Zhang J, Zhang P	Expression and Clinical Implications of LAG-3 in Small Cell Lung Cancer.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology	doi: 10.1096/fj.202502183R
40960558	2025 Sep 17	Ibe OE, Ulasov I, Samoylova S, Reshetov I	Microsatellite instability and PD-L1 expression in sarcomas: current evidence and clinical perspectives.	Medical oncology (Northwood, London, England)	doi: 10.1007/s12032-025-03039-y
40959419	2025	Lackovic LN, Tomic MS, Novakovic M, Turic M, Kajkut A, Macinkovic T, Stanetic M, Glamocak R	Pembrolizumab in the treatment of non-small cell lung cancer-experiences from clinical practice.	Frontiers in medicine	doi: 10.3389/fmed.2025.1635626
40959269	2025	Li JP, Liu YJ, Zhang Y, Ye QW, Xu G, Chong JC, Yin Y, Li Y, Wang SS, Zhou JY, Qian J, Liu SL, Zou X, Chen YG	Comprehensive analytical approach identifies a subtype of CTCF+ tumor-associated neutrophils associated with CRC development and as a biomarker for immunotherapy.	International journal of biological sciences	doi: 10.7150/ijbs.111529
40959247	2025 Sep 11	rgbo RB	Targeting Diacylglycerol Kinase Alpha (DGKα) with New Inhibitors for Enhanced Cancer Immunotherapy.	ACS medicinal chemistry letters	doi: 10.1021/acsmedchemlett.5c00473
40959235	2025 Sep 11	Deng W, Yang Y, Zhou T, Zhu X, Xu B, Zhao X, Huang K, Jin Y, Wang L, Qin M	Discovery of Pyrazole-Containing 4‑Arylindolines as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction.	ACS medicinal chemistry letters	doi: 10.1021/acsmedchemlett.5c00423
40959109	2025	Xun J, Liu Z, Liu B, Jiang X, Yang H, Liu J, Wang B, Gao R, Zhang A, Wu X, Xi Q, Yu X, Zhang Q	KDM6B enhances anti-PD-L1 immunotherapy efficacy by increasing CD8(+) T-cell infiltration in colorectal cancer.	Journal of Cancer	doi: 10.7150/jca.118571
40959084	2025	Chen R, Wang Z, Chen X, Huang Y, Zhang F, Gao T	Personalised immunotherapy strategies informed by single cell profiling in thyroid cancer: a mini review.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1651088
40959065	2025	Tang H, Fu B, Yang Q, Yao J, Zeng K, Feng X, Yang Y, Yi S	Case Report: Split liver transplantation for graft liver failure due to antibody-mediated rejection after immune checkpoint inhibitor therapy.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1556851
40959056	2025	Yuan H, Li Y, Zhao K, Zhao YN, Yao QJ, Geng X, Wang LF, Song HY, Hu HT	Efficacy and safety of DEB-TACE combined with transarterial TQB2450 infusion and oral Anlotinib as first-line treatment in advanced hepatocellular carcinoma: a single-arm phase II study.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1667785
40958881	2025	Cao Y, Shi F, Wei X, Han S, Fang Y	Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China.	Frontiers in oncology	doi: 10.3389/fonc.2025.1542792
40958361	2025 Sep 15	Conforti F, Pala L, Catania C, Zucali PA, Sala I, Perrino M, De Vincenzo F, Cordua N, Canzian J, Tinterri B, Governini E, Bendoni M, Santoro A, Giaccone G, De Pas TM	Avelumab combined with axitinib for patients with advanced thymoma B3 and thymic carcinoma.	Cancer	doi: 10.1002/cncr.70092
40958347	2025 Sep 12	Zhang S, Liu J, Liu J, Lu K	A retrospective analysis of immunotherapy in non-small cell lung cancer patients with targetable genetic mutations.	Medicine	doi: 10.1097/MD.0000000000044144
40958322	2025 Sep 12	Cai M, Liu Y, Tao H, Tang L, Zhao L, Lan W, Liu X, Sheng Z, Peng Y, Sun W, Wu X, Shu Y	Mendelian randomization study: Metabolites as mediators of inflammatory factors in ulcerative colitis.	Medicine	doi: 10.1097/MD.0000000000044206
40958203	2025 Jan-Dec	Huo J, Qi J, Ren Q	Sennoside A Modulates the Ferroptosis and Immune Evasion of Oral Squamous Cell Carcinoma Cells Through Inhibiting the NF-κB Pathway.	Integrative cancer therapies	doi: 10.1177/15347354251375464
40958168	2025 Sep 16	Cai B, Feng X, Luo S, Nurbahati A, Cui H, Peng T, Wang W, Li H, Liu Q, Lu X, Zheng S	5-FU Resistance Facilitates Immune Evasion in Esophageal Squamous Cell Carcinoma Through ADAM10-Mediated PD-L1 Shedding and Tumour Microenvironment Remodelling.	Immunology	doi: 10.1111/imm.70038
40958118	2025 Sep 16	Topi G, Sjölander A, Satapathy SR	Integrating COX-2, stromal PD-L1, and T-cell infiltration enhances prognostic stratification in colorectal cancer.	BMC cancer	doi: 10.1186/s12885-025-14927-x
40957723	2025 Sep 16	Rahimi N, Potluri S, Chitalia V	IGPR-1 Is Phosphorylated on the Immunoreceptor Tyrosine-Based Motif, Stimulates the AKT Pathway and Supports Melanoma Growth.	Biochemistry	doi: 10.1021/acs.biochem.5c00393
40957419	2025 Sep 15	Mattavelli G, Helal M, Cetkovic A, Krämer MJ, Herbert SL, Mielert K, Schlaiß T, Frank A, Riemer E, John M, Del Pilar J, Vasquez M, Kindl L, Swietlik JJ, Gansen BO, Krafft M, Stanojkovska E, Fischer H, Albert US, Bauer J, Delgobo M, Aintablian A, Alattar H, Lutz MB, Meissner F, Oskarsson T, Rasche L, Ramos G, Rosenwald A, Wöckel A, Riedel A	A TLR4-dependent fibroblast-monocyte axis in tumor-draining lymph nodes contributes to metastasis in triple-negative breast cancer.	Immunity	pii: S1074-7613(25)00378-4. doi: 10.1016/j.immuni.2025.08.015
40956795	2025	Read OJ, Bré J, Zhang Y, Mullen P, Elshani M, Harrison DJ	A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death.	PloS one	doi: 10.1371/journal.pone.0331567
40956534	2025 Sep 16	Arima J, Chida K, Wu R, Taniguchi K, McKenery A, Morreale BG, Monell AM, Abrams SI, Ebos JML, Hakamada K, Ishikawa T, Hagihara S, Kimura K, Iwamoto M, Lee SW, Takabe K	ESR1 Expression Negatively Correlates with Immune Cell Infiltration and Response to Immune Checkpoint Inhibitors in Estrogen Receptor-Positive/HER2-Negative Breast Cancer.	Annals of surgical oncology	doi: 10.1245/s10434-025-18260-2
40956367	2025 Sep 16	Tang B, Zhang X, Sun Y, Luo J, Weng Q, Zhang C, Wang Z, Fang S, Xiao Y, Zheng L, Tu J, Qiu R, Yang Y, Zhao Z, Chen W, Chen M, Ji J	Tumor-Targeted FABP5/STING Cascade Promote Radiofrequency Ablation Induced Ferroptosis and Intratumoral Immune Rewiring in Hepatocellular Carcinoma.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	doi: 10.1002/advs.202507864
40956358	2025 Sep 16	Unver N, Uluturk S, Tavukcuoglu E, Duymaz Yilmaz E, Kaymaz Y, Esendagli G	The impact of aspirin on PD-L1 expression and alteration of M2 polarization in non-small cell lung cancer.	Inflammation research : official journal of the European Histamine Research Society ... [et al.]	doi: 10.1007/s00011-025-02091-8
40956279	2025 Sep 16	Turashvili G, Karnezis AN, Hulkower KI, Hebert C, Harik L, Crothers B, Giannico G, Deeb KK, Hanley K, Ganesan R, Mills A, Buza N	Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of Gynecologic Origin: The Updated College of American Pathologists Protocol.	Archives of pathology & laboratory medicine	doi: 10.5858/arpa.2025-0157-CP
40954256	2025 Sep 15	Che S, He L, Chen Q, Mo Y, Li F, Huang J, Ruan Z	TUG1 targeting enhances anticancer immunity thereby facilitating lenvatinib efficacy in hepatocellular carcinoma.	Genes and immunity	doi: 10.1038/s41435-025-00358-y
40954246	2025 Sep 15	Fujii T, Sakurai M, Shimizu H, Izumi A, Kimura K, Shono K, Tanoue S, Okada Y, Kako S, Matsui S, Sakaida E, Jinguji A, Ouchi F, Najima Y, Kobayashi T, Tachibana T, Tanaka M, Iwata S, Onizuka M, Yano S, Hatano K, Hagihara M, Aotsuka N, Fujisawa S, Takahashi S, Kobayashi N, Kikuchi T, Tanaka K, Kataoka K, Kanda Y	Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation.	Bone marrow transplantation	doi: 10.1038/s41409-025-02718-8
40954075	2025 Sep 15	Cao S, Sun Z, Hu W, Xue D, Yang Z, Duan P, Peng H, Fu YX, Liang Y	Dual targeting OX40 and IL-2 receptor enhances antitumor activity through tumor-infiltrating Treg depletion and CD8(+) T-cell proliferation.	Journal for immunotherapy of cancer	doi: 10.1136/jitc-2025-011638
40953759	2025 Sep 13	Alibrahim MN, Gloghini A, Carbone A	Predictors of first line treatment failure in classic Hodgkin lymphoma: A comprehensive review.	Critical reviews in oncology/hematology	doi: 10.1016/j.critrevonc.2025.104943
40952277	2025 Sep 1	Al-Omari MM, Okour A, Al-Qaoud KM, Al-Omari T, Marashdeh RH, Bataineh NM	Effect of Alpha1 Antitrypsin on PD-1/PD-L1 and EGFR in Colitis-Associated Colorectal Cancer BALB/c Mouse Model.	Asian Pacific journal of cancer prevention : APJCP	doi: 10.31557/APJCP.2025.26.9.3229
40951848	2025 Jul-Sep	Hariprasad M, Rao M, Elhence PA, Bharti JN, Singh P, Yadav G, Nalwa A, Ramalingam H, Goel AD	Expression of Programmed Cell Death Ligand 1 and Mismatch Repair Status in Ovarian Carcinomas.	Journal of mid-life health	doi: 10.4103/jmh.jmh_102_25
40951735	2025 Sep	Nguyen TT, Zhang B, Zhong L, Liang X, Bo L	Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next-Generation PD-1 Immunotherapy.	Chronic diseases and translational medicine	doi: 10.1002/cdt3.70017
40951454	2025	Xie YL, Ke LF, Zhang WW, Kang F, Lu SY, Wu CY, Zhu HH, Wang JC, Chen G, Chen YP	Comprehensive Analysis of Tumor Microenvironment and PD-L1 Expression Associations with Clinicopathological Features and Prognosis in Diffuse Large B-Cell Lymphoma.	Blood and lymphatic cancer : targets and therapy	doi: 10.2147/BLCTT.S545717
40950662	2025 Aug 31	Jing S, Dong W, Zhan C	Value of ZSCAN9 in the treatment and survival prediction of hepatocellular carcinoma: a bioinformatics study.	Translational cancer research	doi: 10.21037/tcr-2025-1597
40950404	2025	Kyriakidis NC, Echeverría CE, Bautista J, Rivera-Orellana S, Ramos-Medina MJ, Salazar-Santoliva C, Izquierdo-Condoy JS, Ortiz-Prado E, Guerrero S, López-Cortés A	Reprogramming cancer immunity with next-generation combination therapies.	Frontiers in cell and developmental biology	doi: 10.3389/fcell.2025.1652047
40950333	2025 Aug 30	Yan B, Zhang P, Zu Q, Liu S, Wang P, Wei Y, Liu J, Zhang S, Wang Y, Han Z	NKAP overexpression promotes gastric cancer immune escape by inducing IL-10 secretion from mature dendritic cells during anti-PD-L1 therapy.	Journal of gastrointestinal oncology	doi: 10.21037/jgo-2025-491
40950232	2025 Sep 3	Qian W, Wei X, Barros AJ, Ye X, Yu Q, Young SP, Yeatts EV, Park Y, Li C, Almeida-Santos G, Tang J, Narasimhan H, Kirk NA, Li Y, Li L, Chen P, Sturek JM, Park KS, Chen W, Cheon IS, Sun J	Respiratory viral infections prime accelerated lung cancer growth.	bioRxiv : the preprint server for biology	pii: 2025.09.02.672566. doi: 10.1101/2025.09.02.672566
40949471	2025	Lima Feldmann JF, Lima Feldmann JH, Hidalgo-Filho CM, de Almeida Robatto AA, Araújo BJ, Viana PCC, de Castro Junior G	Immunotherapy and local therapies in metastatic laryngeal cancer management: a case report.	Ecancermedicalscience	doi: 10.3332/ecancer.2025.1947
40949131	2025	Dorji JP, Chen Q, Perera SG, Aijaz F, Li P, Sania T, Matsui H, Awah CU	c-MYC mRNA destabilization inhibited lethal pancreatic cancer in vivo with significant survival outcomes.	Frontiers in pharmacology	doi: 10.3389/fphar.2025.1630476
40949053	2025	soy M	Immature Granulocytes and Nivolumab Outcomes in Stage IV Non-Small Cell Lung Cancer: Insights by Tumor Subtype.	Clinical Medicine Insights. Oncology	doi: 10.1177/11795549251371094
40948848	2025 Aug 31	Petrelli F, Dottorini L, Rossitto M, Meriggi F, Cherri S, Zaniboni A, Ghidini A	A systematic review and network meta-analysis of immune checkpoint inhibitors in operable NSCLC: neoadjuvant, adjuvant, or perioperative?	Translational lung cancer research	doi: 10.21037/tlcr-2025-185
40948837	2025 Aug 31	Dong Z, Zuo R, Guo Y, Wen X, Zhao G, Jiang Z	STK11/KEAP1 co-mutations in SMARCA4-mutant advanced non-small cell lung cancer: genetic characteristics and impact on immunotherapy efficacy.	Translational lung cancer research	doi: 10.21037/tlcr-2025-305
40948827	2025 Aug 31	Wu C, Ma L, Wang Y, Bidzińska J, Wang Y	Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1.	Translational lung cancer research	doi: 10.21037/tlcr-2025-800
40948781	2025	Zhu H, Huang Y, Wang X, Xiang W, Xie Y	Trends and hotspots in research related to tumor immune escape: bibliometric analysis and future perspectives.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1604216
40948764	2025	Soncini D, Marimpietri D, Ladisa F, Lai F, Airoldi I, Gramignoli R, Cea M, Morandi F	Bone marrow-derived extracellular vesicles from multiple myeloma patients promote adaptive immune dysfunction via HLA-G, PD-1, and PD-L1.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1640168
40948759	2025	Deng X, Huang S	Microbiome-macrophage crosstalk in the tumor microenvironment: implications for oral squamous cell carcinoma progression and therapy.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1651837
40948544	2025	Fang Q, Yuan J, Zhang X, Lin L	LncRNA MIR31HG facilitates immune escape in head and neck squamous cell carcinoma by promoting heterotypic cell-in-cell formation.	American journal of cancer research	doi: 10.62347/MMZP1913
40948543	2025	Wang Y, Zeng Y, Chen P, Xu B, Liu X, Su Z	Adora1 promotes colon cancer immune evasion via Irf1-PD-L1 signal axis.	American journal of cancer research	doi: 10.62347/ADLH2257
40948532	2025	Chi L, Li M, Zhou H, Wang WJ, Wang B, Sun X	Comparative effectiveness of perioperative strategies for resectable gastric and gastroesophageal junction cancer: a Bayesian network meta-analysis.	American journal of cancer research	doi: 10.62347/ECKT5511
40948525	2025	Xu H, Cai F, Xu L, Jiang D, Wang G, Zhang X, Zhang Y	RNF200 enhances radiotherapy sensitivity by modulating PD-L1 stability in tumor-associated macrophages of lung cancer.	American journal of cancer research	doi: 10.62347/BIQP4822
40948428	2025 Sep 15	Bryl M, Stencel K, Knetki-Wróblewska M, Krzakowski M	Efficacy and safety of first-line immune checkpoint inhibitors in patients with PD-L1 < 1% metastatic non-small-cell lung cancer - implications for daily clinical practice.	Expert review of anticancer therapy	doi: 10.1080/14737140.2025.2557610
40948045	2025 Sep 15	Yan D, Lyu B, Yu J, Bao S, Zhang Z, Zhou M, Sun J	Decoding fatal toxic effects in checkpoint inhibitor therapy using real-world pharmacovigilance data and machine learning.	British journal of pharmacology	doi: 10.1111/bph.70195
40947866	2025 Sep 15	Tao JJ, Vasan N	A New VISTA in Intracellular Checkpoint Signaling in Triple-Negative Breast Cancer.	Cancer research	doi: 10.1158/0008-5472.CAN-25-2286
40947536	2025 Sep 15	Li H, Parimi V, Johnson B 3rd, Kamanda S, Baraban E, Hoffman-Censits J, Kates M, McConkey DJ, Hahn NM, Matoso A	Clinicopathologic and Prognostic Features of Sarcomatoid Urothelial Carcinoma: A Retrospective Study of 136 Patients With Emphasis on Early-Stage (pT1) Disease.	The American journal of surgical pathology	doi: 10.1097/PAS.0000000000002468
40947473	2025 Sep 15	Fathah DE, Ejaz S	Role of tumor microenvironment in cancer promotion, development of drug resistance and cancer treatment.	Journal of the Egyptian National Cancer Institute	doi: 10.1186/s43046-025-00317-8
40947372	2025 Aug 20	Huang WW, Cheng YJ, Yuan SS, Liu Y, Liu FR	Characterization of the Tumor Immune Microenvironment in HER2-Positive Colorectal Cancer: Association With Prognostic and Therapeutic Implications.	Clinical colorectal cancer	pii: S1533-0028(25)00072-6. doi: 10.1016/j.clcc.2025.08.004
40947345	2025 Aug 26	Desai A, McNeeley E, Alhushki S, Haught M, Masjoan Juncos JX, Patel D, Brand J, McManus L, Bae S, Khalil M, Boumber Y	DISCERN: A Randomized Pilot Study Comparing Dual Versus Single Immune Checkpoint Blockade Plus Chemotherapy in PD-L1 Negative Advanced Non-Small Cell Lung Cancer.	Clinical lung cancer	pii: S1525-7304(25)00220-7. doi: 10.1016/j.cllc.2025.08.013
40946951	2025 Sep 12	Li ZM, Zheng YF, Xu PH, Wang JY, He RL, Li HX, Kuang YK, Bai LH, Tang KJ	Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database.	European journal of pharmacology	doi: 10.1016/j.ejphar.2025.178156
40946796	2025 Sep 12	Dehghani S, Chacon M, Forouzanfar K, Lee S, Narimatsu A, Singh RB, Musayeva A, Kahale F, Anchouche S, Heydarian N, Bhullar S, Dohlman TH, Chen Y, Blanco T, Dana R	Role of PD-L1 in Regulatory T Cell-Mediated Suppression of Corneal Neovascularization.	The American journal of pathology	pii: S0002-9440(25)00335-9. doi: 10.1016/j.ajpath.2025.08.008
40946794	2025 Sep 12	Das A, Tomita N, Syme KJ, Ma W, O'Connor P, Corbett KN, Ren B, Liu X, Hassanpour S	Cross-Modality Learning for Predicting IHC Biomarkers from H&E-Stained Whole-Slide Images.	The American journal of pathology	pii: S0002-9440(25)00341-4. doi: 10.1016/j.ajpath.2025.08.014
40946586	2025 Sep 13	Jia D, Wang P, Zheng S, Lei Z, Xu W, Wang Y, Pan X, Feng Q, Yang J	KRAS mutations promote PD-L1-mediated immune escape by ETV4 in lung adenocarcinoma.	Translational oncology	doi: 10.1016/j.tranon.2025.102525
40946581	2025 Sep 13	Alampi MM, Kozlíková M, Mariangeli M, Civita S, Delcanale P, Mussini A, Diaspro A, Bianchini P, Weyergang A, Skarpen E, Berg K, Viappiani C, Abbruzzetti S, Selbo PK	Light-enhanced cytotoxicity and intracellular trafficking of the PD-L1-targeting photoimmunoconjugate EITC-atezolizumab.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie	doi: 10.1016/j.biopha.2025.118550
40946314	2025 Sep 12	Rokan A, Diniz MO, de Las Heras JI, Hall C, Noorsaeed S, Bennett CL, Secrier M, Kassiotis G, Fassati A	Evolution of a melanoma that escapes allogeneic rejection.	Cell reports	doi: 10.1016/j.celrep.2025.116288
40946254	2025 Sep 14	Lu S, Wang J, Yu Y, Yu X, Hu Y, Wangjun L, Li X, Liu Y, Li W, Qu X, Bao Y, Wang M	First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 ≥ 50% Subgroup Analysis from the RATIONALE-304 Trial.	Oncology and therapy	doi: 10.1007/s40487-025-00378-8
40945738	2025 Sep 11	Wong JH, Rivas S, Choi J, Wang X, Salloum L, Wu S, Choi S, Segal S, Goldberg RH, McLellan BN	Oral Immune-Related Adverse Events Associated with PD-1 and PD-L1 Inhibitor Therapies: A Retrospective, Single-Institution Study.	Journal of the American Academy of Dermatology	pii: S0190-9622(25)02800-2. doi: 10.1016/j.jaad.2025.09.018
40945303	2025 Sep 8	Mandalà M, Ugolini F, Caldirola L, Rulli E, Manca A, Sini MC, Simi S, Baroni G, Costabile S, De Giorgi V, Cossu A, Bellezza G, Guadagno A, Spagnolo F, Gianatti A, Ghiorzo P, Palmieri G, Massi D	Tumour microenvironment heterogeneity in primary and metastatic paired melanoma samples and its correlation with genetic features and prognosis.	European journal of cancer (Oxford, England : 1990)	doi: 10.1016/j.ejca.2025.115755
40944992	2025 Sep 12	Hou Z, Lan M, Zhu YX, Xue ZH, He M, Ma RX, Liu S, Wu L, Wang Y, Wan G, Li BS, Chen BQ, Wang QF	Clinical characteristics and prognosis of pulmonary lymphoepithelioma-like carcinoma: a multicenter cohort study of 1106 cases.	ESMO open	doi: 10.1016/j.esmoop.2025.105769
40944826	2025 Sep 13	Yang Y, Liu R, Sun Q, Chen Z, Fan W	Enterococcus faecalis and lipoteichoic acid up-regulated PD-L1 of macrophage through TLR and IRE1 α/XBP1 signaling axis.	Odontology	doi: 10.1007/s10266-025-01202-5
40944812	2025 Sep 13	Shen C, Li W, Shi J, Wu Y, Yan Y	Knockdown of circ_0000372 elevates PD-L1 level through sponging miR-488-3p to restrain cell viability, motility and immune escape in gastric cancer.	Journal of molecular histology	doi: 10.1007/s10735-025-10598-x
40944777	2025 Sep 13	Younis SMD, Shareef A, Bishoyi AK, Oweis R, Malathi H, Singh A, Sahoo S, Chauhan AS, Sameer HN, Yaseen A, Athab ZH, Adil M	Targeting tumor immune evasion: the role of PD-L1 siRNA in advancing cancer immunotherapy.	Medical oncology (Northwood, London, England)	doi: 10.1007/s12032-025-03025-4
40944717	2025 Sep 13	Du W, Xiao B, Yang X, Zhan J, Sun H, Yang Y, Fang W, Huang Y, Sun D, Hong S, Zhang L	Tertiary lymphoid structures gene signature predicts response to immunotherapy plus chemotherapy in advanced non-small cell lung cancer.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-025-04165-2
40944710	2025 Sep 13	Dutta N, Svensson J, Saad GA, Mello M, Eklund EA, Altinönder I, Torstensson P, Sayin VI, Rohlin A, Luche H, Hallqvist A, Raghavan S	High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-025-04086-0
40944087	2025 Sep 8	Todor SB, Mihaila RG	Cytokine Landscapes, Immune Dysregulation, and Treatment Perspectives in Philadelphia-Negative Myeloproliferative Neoplasms: A Narrative Review.	Journal of clinical medicine	doi: 10.3390/jcm14176328
40943961	2025 Sep 2	Djordjevic F, Ljujic K, Stanic N, Nikolic N, Markovic I, Spasic J	Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%).	Journal of clinical medicine	doi: 10.3390/jcm14176200
40943939	2025 Sep 1	Andrei GM, Motaș N, Rădulescu VM, Ionovici N, Bunescu M, Zob DL, Biciușcă V, Dumitrescu F, Marcu EA, Cioboată R, Olteanu M	EBUS-TBNA for Diagnosis and Staging of Lung Cancer: A Retrospective Regional Analysis Integrating Clinical and Molecular Data (EXPoSURE Score).	Journal of clinical medicine	doi: 10.3390/jcm14176179
40943568	2025 Sep 5	Wang X, Lu X, Liu C, Cheng H, Tan X	A Study on the Efficacy and Pharmacological Mechanism of Liposome Complexes Containing STING Agonist and Anti-PD-L1 Nanobody in Inhibiting HCC.	International journal of molecular sciences	doi: 10.3390/ijms26178649
40943560	2025 Sep 5	Cozac-Szőke AR, Tinca AC, Negovan A, Vilaia A, Cozac DA, Cocuz IG, Sabău AH, Hagău RD, Chiorean DM, Lazar AB, Turdean S, Szász EA, Tomuț AN, Cotoi OS	Comprehensive Analysis of SIGLEC-15 and PD-L1 Expression Identifies Distinct Prognostic Profiles in Gastric Cancer.	International journal of molecular sciences	doi: 10.3390/ijms26178637
40943476	2025 Sep 3	Shinohara Y, Nakayama S, Aoki M, Nishio J	Histiocytic Sarcoma: A Review and Update.	International journal of molecular sciences	doi: 10.3390/ijms26178554
40943394	2025 Aug 31	Ayasa Y, Alajrami D, Idkedek M, Tahayneh K, Akar FA	The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment.	International journal of molecular sciences	doi: 10.3390/ijms26178472
40943153	2025 Aug 25	Varnai R, Szebeni GJ, Gémes N, Schwarcz A, Molnar T, Olah C, Csecsei P	Immune Checkpoint Dysregulation in Aneurysmal Subarachnoid Hemorrhage: A Prospective Study of sCTLA-4 and sPD-L1 as Biomarkers of Symptomatic Vasospasm.	International journal of molecular sciences	doi: 10.3390/ijms26178228
40943145	2025 Aug 24	Öztan G, İşsever H, İşsever T	The Role of miRNAs in the Differential Diagnosis of Alzheimer's Disease and Major Depression: A Bioinformatics-Based Approach.	International journal of molecular sciences	doi: 10.3390/ijms26178218
40943144	2025 Aug 24	Ghebeh H, Mirza JY, Al-Tweigeri T, Al-Alwan M, Tulbah A	Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44(hi)/CD24(lo)-ALDH1(hi) as an Independent Prognostic Factor After Neoadjuvant Chemotherapy.	International journal of molecular sciences	doi: 10.3390/ijms26178219
40941651	2025 Aug 26	Sanguedolce F, Cormio A, Zanelli M, Zizzo M, Palicelli A, Falagario UG, Milanese G, Galosi AB, Mazzucchelli R, Cormio L, Carrieri G	Diagnostic, Prognostic, and Predictive Tissue Biomarkers in Urothelial Carcinoma In Situ: A Narrative Review.	Diagnostics (Basel, Switzerland)	doi: 10.3390/diagnostics15172163
40941632	2025 Aug 25	Li B, Huang L, Huang J, Li J	An Update of Immunohistochemistry in Hepatocellular Carcinoma.	Diagnostics (Basel, Switzerland)	doi: 10.3390/diagnostics15172144
40941037	2025 Sep 8	Di Grazia G, Dri A, Grieco A, Martinelli C, Palleschi M, Martorana F, Barchiesi G, Arpino G, De Angelis C, De Laurentiis M, Del Mastro L, Puglisi F, Vigneri P, Giuliano M	Unlocking the Potential of Immune Checkpoint Inhibitors in HR+/HER2- Breast Cancer: A Systematic Review.	Cancers	doi: 10.3390/cancers17172940
40941018	2025 Sep 5	Natarajan U, Rathinavelu A	Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells.	Cancers	doi: 10.3390/cancers17172919
40941007	2025 Sep 5	Golban C, Blaga CM, Varga NI, Negru AG, Hutanu D, Saftescu S, Negru SM	Inflammation-Based Prognostication in Advanced-Stage NSCLC: A Retrospective Cohort Study.	Cancers	doi: 10.3390/cancers17172910
40940992	2025 Sep 3	Guo M, Jeon WJ, Joung B, Tai D, Gavralidis A, Elliott A, Baca Y, de Semir D, Liu SV, Reeves M, Mirshahidi S, Mirshahidi H	Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLC.	Cancers	doi: 10.3390/cancers17172895
40940918	2025 Aug 28	Mahmood U, Josephides E, Chitnis M, Skwarski M, Gennatas S, Ghosh S, Spicer J, Karapanagiotou E, Ahmad T, Forster M, Jamal-Hanjani M, Benafif S, Swanton C, Lee SM, Papadatos-Pastos D, Georgiou A, Coupe N	Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.	Cancers	doi: 10.3390/cancers17172819
40940902	2025 Aug 27	Kawczak P, Feszak IJ, Bączek T	Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.	Cancers	doi: 10.3390/cancers17172805
40940890	2025 Aug 27	Hilliard AL, Russell TD, Mendonca P, Soliman KFA	Targeting the Tumor Immune Microenvironment in Triple-Negative Breast Cancer: The Promise of Polyphenols.	Cancers	doi: 10.3390/cancers17172794
40940861	2025 Aug 25	Golban C, Susa SR, Varga NI, Ivan CS, Schirta PO, Schirta NC, Negru AG, Saftescu S, Negru SM	The Impact of Body Composition on Outcomes in NSCLC Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review.	Cancers	doi: 10.3390/cancers17172765
40940830	2025 Aug 22	Daniels H, Hassan M, Babiker O, Rowley W, Qaisar A, Phillips E, Griffin E, Bell C, Baraka B, Acharige S, Aquino M, Plant R, Mencel J, Chan S, Parslow D, Arora A, Scott-Brown M, Khakoo S, Braconi C, Palmer D, Ma YT, Sivakumar S	UK Real-World Evidence of Using Durvalumab Plus Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer via an Early Access Scheme.	Cancers	doi: 10.3390/cancers17172732
40940644	2025 Sep 12	Kamel AM, Almuslimani AM, Kandil EZ, Hanafy M, Samra MA, Madney YM, Osman RA	PD1/PDL1 and TIM3/Gal9 expression in acute lymphoblastic leukemia: Gal-9 expression on leukemia stem cells as an independent prognostic parameter.	BMC cancer	doi: 10.1186/s12885-025-14856-9
40940553	2025 Sep 12	Gong L, Tian L, Li H, Zhou K, He H, Xiao S, Zhu Y, Gong Z, Cui K, Zhang Y	FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy.	Oncogene	doi: 10.1038/s41388-025-03558-y
40940136	2025 Sep 12	Regan MM, Ascierto PA MD, Lipson EJ, Palaia J, Moshyk A, Selvan A, Lao CD, Atkins MB MD, McDermott DF, Potluri R, Ranjan S, Bilthare S, Long GV, Stephen Hodi F, Tawbi H, Schadendorf D	Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.	Journal for immunotherapy of cancer	pii: e012747. doi: 10.1136/jitc-2025-012747
40939949	2025 Sep 10	Cheng N, Wang B, Xu J, Wang Z, Xue L	Clinicopathological characteristics and immune infiltration analysis of esophagogastric junction adenocarcinoma with alterations in SWI/SNF complex.	Human pathology	doi: 10.1016/j.humpath.2025.105930
40939862	2025 Sep 10	Chen P, Li HM, Huang CY, Liu JJ, Luo LY, Luo J, Huo XJ, Huang M, Yin YL, Mou L, Ouyang YC	A universal single-plasmid, single-promoter system for efficient protein display and RNA encapsulation in MS2 virus-like particles.	Journal of biotechnology	doi: 10.1016/j.jbiotec.2025.09.004
40939189	2025 Sep 12	Shi J, Huang S, Zhou Y, Zheng G, Zhang Z, Fan X, Shen J	SPP1+ Neutrophils Mediate Resistance to lmmune Checkpoint Blockade in BAP1-Inactivated Tumors.	Cancer research	doi: 10.1158/0008-5472.CAN-24-4962
40939177	2025 Sep 12	Xia Z, Liu W, Guo D, Chen L, Zhao M, Zhao Y, Zhang J, Xia L, Zou Y, Sun P, He B, Tang H, Chen L	CircADAMTS12 Inhibits the Anti-Tumor Activity of Microglia to Enable Metastatic Colonization in the Brain.	Cancer research	doi: 10.1158/0008-5472.CAN-25-0738
40938891	2025	Bach CA, Hossain MN, Chaudhari IJ, Verrillo CE, Naranjo NM, Amoroso I, Testa A, Sey S, Kelly WK, Bellis SL, Lorico A, Blidner AG, Rabinovich GA, Languino LR	A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer.	PloS one	doi: 10.1371/journal.pone.0329014
40938876	2025	Huang Q, Ye B, Ye Z, Huang S, Xue J, Cui F, Jiang T, Sun L, Zeng Y, Wang S, Chen Y, Tang H	Role of c-Myc activating the transcription of PD-L1 in immune escape during benzene-induced malignant transformation of human lymphoblasts.	PloS one	doi: 10.1371/journal.pone.0332277
40938752	2025 Sep 10	Liu B, Wu Y, Xiang A, Yu Y, Song S, Zhang Y, Gu J, Lu H, Xu P, Liu F, Ruan Y	The hexosamine biosynthetic pathway drives tumor immune evasion via translational control of PD-L1 at the elongation level.	Cell reports	doi: 10.1016/j.celrep.2025.116249
40937638	2025 Sep 12	Ayoub M, Abou Jaoude C, Ayoub M, Hamade A, Rima M	The Immune System and Cellular Senescence: A Complex Interplay in Aging and Disease.	Immunology	doi: 10.1111/imm.70036
40937576	2025 Nov	Bugia L, Affolter A, Kern J, Sohn E, Jungbauer F, Fleckenstein J, Lammert A, Rotter N, Scherl C	Irradiation‑induced cellular senescence is linked to pro‑survival signaling and checkpoint regulation in a 2D and 3D model for head and neck cancer.	Oncology reports	pii: 151. doi: 10.3892/or.2025.8984
40937253	2025 Aug	Bernard ME, Rueckert J, Pierre-Charles JZ, Miller JZ, Yang E	Concurrent Radiation With Nivolumab and Chemotherapy for Nodal-Only Distant Metastatic Stage IV Esophageal Carcinoma.	Cureus	doi: 10.7759/cureus.89807
40937192	2025 Sep	Zhang Y, Wang N, Zhang L, Zhuang Y, Xin Q, Gu X, Jiang C, Wu J	Serotonin (5-Hydroxytryptamine): Metabolism, Signaling, Biological Functions, Diseases, and Emerging Therapeutic Opportunities.	MedComm	doi: 10.1002/mco2.70383
40936918	2025	Xia W, Zhang X, Wang Y, Huang Z, Guo X, Fang L	Progress in targeting tumor-associated macrophages in cancer immunotherapy.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1658795
40936907	2025	Tong C, Wu Y, Wu R	New dimensions of PD-1/PD-L1 inhibitor combination therapy in cancer treatment: current advances and future perspectives.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1616872
40936903	2025	Fan S, Zhao Z, Meng Q, Wang H, Yu B, Niu W	Immune activation following PD-L1 inhibitor plus chemoradiotherapy in locally advanced rectal cancer: a retrospective, single-arm study.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1619043
40936894	2025	Ma Y, Zhang L, Liu W	Immunosuppressive tumor microenvironment and advance in immunotherapy in melanoma bone metastasis.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1608215
40936705	2025	Zhou Z, Zhou Q	Immunotherapy resistance in triple-negative breast cancer: Molecular mechanisms, tumor microenvironment, and therapeutic implications.	Frontiers in oncology	doi: 10.3389/fonc.2025.1630464
40936154	2025 Aug	Jiang XH, Chen YJ	[The Role of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Lymphoma--Review].	Zhongguo shi yan xue ye xue za zhi	doi: 10.19746/j.cnki.issn.1009-2137.2025.04.043
40936109	2025 Sep 11	Wu Z, Zheng P, Xiao Y, Wang Q, Pan X, Zhou X, Lv Y, Xiao J, He Y, Huang T, Lei P	Targeted Degradation of sGRP78 Alleviates the Immunosuppressive Tumor Microenvironment.	Advanced science (Weinheim, Baden-Wurttemberg, Germany)	doi: 10.1002/advs.202509921
40935873	2025 Sep 11	Zhang J, Li X, Yu X, Jiang W, He X, Mei C, Ou C	Identification of CD159A as a prognostic and immune biomarker in kidney renal clear cell carcinoma.	Scientific reports	doi: 10.1038/s41598-025-18515-8
40935646	2025 Jul 20	Chen X, He W, Yang N, Xiong L, Wang H, Liu P, Xie B, Zhou J	[Histological Transformation from Non-small Cell Lung Cancer to Small Cell Lung Cancer Induced by Immune Checkpoint Inhibitor Therapy: A Case Report and Literature Review].	Zhongguo fei ai za zhi = Chinese journal of lung cancer	doi: 10.3779/j.issn.1009-3419.2025.101.12
40935273	2025 Sep 10	Cai Y, Tu Y, Cheng H, Yu J	Investigating the interaction mechanism of five flavonoids and PD-L1 based on multi-spectroscopy and molecular dynamics.	Chemico-biological interactions	doi: 10.1016/j.cbi.2025.111741
40935246	2025 Sep 9	Kusano K, Uno K, Tamahara T, Asano N, Sudo K, Tanabe M, Ogasawara K, Kanno T, Koike T, Shimizu R, Masamune A	Metabolic syndrome develops cardia cancer via nuclear factor-E2-related factor 2-programmed death-ligand 1 signaling.	Cellular and molecular gastroenterology and hepatology	doi: 10.1016/j.jcmgh.2025.101629
40934933	2025 Sep 8	Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, Häfliger S, Parkes A, Zhang Y, Hamidi A, Thompson CG, Wermke M	Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.	The Lancet. Oncology	pii: S1470-2045(25)00480-2. doi: 10.1016/S1470-2045(25)00480-2
40934540	2025 Sep 10	Liu Y, Li X, Li B, Wang Y, Zhang Z, Wang Z, Gu M, Li W, Zhang T	Dose-dependent efficacy of CX1003 in NSCLC immunotherapy: High dose for T cell response, low dose for apoptosis.	International immunopharmacology	doi: 10.1016/j.intimp.2025.115520
40933637	2025 Oct	Danesh K, Hu JC, Kokot N, Goldstein Z, DeClerck B, Beutler B, Jadvar H, Butcher K, In GK	A case of cutaneous angiosarcoma with intradermal metastases responding to PD-1 inhibition-based immunotherapy.	JAAD case reports	doi: 10.1016/j.jdcr.2025.05.046
40932925	2025 Sep	Velazquez V, Hakim MN, Brockhoff H, Maharaj S	Multimodal management of PD-L1 positive sinonasal inverted papilloma with malignant transformation.	World journal of otorhinolaryngology - head and neck surgery	doi: 10.1002/wjo2.221
40932382	2025 Sep 11	Llerena P, Samarah H, Nunes K, Lin Z, Bridgham K, Tekumalla S, Jain A, Harshyne L, Shukla SK, Vathiotis I, Tuluc M, Gargano S, Eisenbrey JR, Keith S, Cognetti DM, Bar-Ad VC, Luginbuhl AJ, Axelrod R, Vadigepalli R, Yang H, Whitaker-Menezes D, Roche M, Mahoney MG, Argiris A, Solomides C, Johnson JM, Barbirou M, Miller A, South AP, Mitra R, Linnenbach AJ, Martinez-Outschoorn U, Curry JM	Extracellular matrix-myCAF signatures correlate with resistance to neoadjuvant aPD-L1 immune checkpoint inhibition with durvalumab + metformin in HPV+ HNSCC.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-1098
40932365	2025 Sep 11	Kolberg HC, Schumacher J, Erber R, Braun M, Fasching PA, Grischke EM, Schem C, Lux MP, Deryal M, Hoffmann O, Heinrich B, Kunz G, Lübbe K, Krabisch P, Hartmann A, Räth P, Kasimir-Bauer S, Kolberg-Liedtke C	Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple negative breast cancer (TNBC) - the neoMono trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-1288
40932352	2025 Sep 11	Balasubramanian A, Marceaux C, Kanwal S, Tarasova I, Batey D, Senko C, Asadi K, Yokote K, Palmer J, Christie M, Gunjur A, Arulananda S, Parakh S, Adams D, Phipson B, Grimmond S, Cebon J, Asselin-Labat ML, John T	Effect of CVA21, an Oncolytic Virus, in combination with Pembrolizumab on immunogenicity and the tumour microenvironment in advanced NSCLC: a phase I/II trial.	Clinical cancer research : an official journal of the American Association for Cancer Research	doi: 10.1158/1078-0432.CCR-25-1449
40932107	2025 Sep	Wang K, Shen Y, Hu C, Xu F, Wang Q, Gao Y, Zhou L	Population Pharmacokinetics and Exposure-Response Analysis of Serplulimab in Small Cell Lung Cancer Patients.	Clinical and translational science	doi: 10.1111/cts.70322
40932092	2025 Sep 11	Cao J, Yu Y, Han K, Wang B, Ma B, Zhang L, Sun B, Li Y, Li J, Ma Y, Zhi J, Zhao J, Wang W	Persistent Membrane-Anchored Oligomeric Peptides with Nanopore Formation for Targeted Immune Modulation.	Angewandte Chemie (International ed. in English)	doi: 10.1002/anie.202507700
40931833	2025 Sep 11	Chen Y, Tang D	New strategies to enhance the efficacy of PD-1/PD-L1 inhibitors in treating microsatellite stable colorectal cancer.	Future oncology (London, England)	doi: 10.1080/14796694.2025.2558287
40931559	2025 Sep 12	Zou Y, Zhang L, Yang P, Yu G, Sun D	Clinicopathological Features of Non-HPV-associated Common Differentiated Penile Squamous Cell Carcinoma: A Study of 55 Patients.	Applied immunohistochemistry & molecular morphology : AIMM	doi: 10.1097/PAI.0000000000001279
40931505	2025 Sep 8	Pérez-Osorio IN, Hernández-Aceves JA, Espinosa-Cerón JA, Saavedra R, Fragoso G, Sciutto E	Neuro-immune-endocrine modulation of T-cell exhaustion in Central Nervous System parasitic diseases: insights from Toxoplasmosis and Neurocysticercosis.	Neuroimmunomodulation	doi: 10.1159/000548276
40931215	2025 Sep 11	Zhang H, Liu X, Lei J, Tian F, Liu X, Lv F, Kang S, Lan K, Wang J, Yan X, Ni Y	Circ_0074158 and QKI6: A regulatory axis for PD-L1 ubiquitination and immune evasion in NSCLC.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-025-04152-7
40931126	2025 Sep 11	Huang X, Chen X, Chen J, Hu C, Chen H, Chen H, Fang J, Ye Z, Du Y, Yu P, Huang L	Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study.	Cancer immunology, immunotherapy : CII	doi: 10.1007/s00262-025-04161-6
40931050	2025 Sep 10	Wei X, Wu J, Cao W, Chen Q, Shao Z, Hu C, Zhang Y, Weng W, Meng T, Meng X, Liang T, Zhang Q	A novel FAP-targeting antibody-exatecan conjugate improves immune checkpoint blockade by reversing immunosuppressive microenvironment in pancreatic cancer.	Oncogene	doi: 10.1038/s41388-025-03567-x
40930564	2025 Sep 9	Rauber C, Roberti MP, Vehreschild MJ, Tsakmaklis A, Springfeld C, Teufel A, Ettrich T, Jochheim L, Kandulski A, Missios P, Mohr R, Reichart A, Waldschmidt DT, Sauer LD, Sander A, Schirmacher P, Jäger D, Michl P, Dill MT	Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).	BMJ open	doi: 10.1136/bmjopen-2024-097802
40928910	2025 Sep 10	Li YC, You HR, Huang YA	scGraphDap: Integrating Functional State Pseudo-labels and Graph Structure Learning for Robust Cell Type Annotation in Tumor Microenvironments.	IEEE journal of biomedical and health informatics	doi: 10.1109/JBHI.2025.3607687
40928867	2025 Sep 3	Deng Y, Huang Y, Cai S, Huang C, Liu W, Jia R, Sui Z, Zou H, Yu Z, Guo X	Pembrolizumab treatment in SMARCA4-deficient nonsmall cell lung cancer: high tumor mutational burden and programmed death-ligand 1(+) expression on circulating tumor cells for real-time monitoring: a case report.	Anti-cancer drugs	doi: 10.1097/CAD.0000000000001758
40928729	2025 Sep 10	Karlsson L, Ciccolini J, Ter Heine R, Centanni M	Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens.	PharmacoEconomics	doi: 10.1007/s40273-025-01535-7
40928654	2025 Sep 10	Ma Y, Ding J, Chen Y	The effect of CD40 agonist antibody therapy on the pancreatic cancer microenvironment.	Naunyn-Schmiedeberg's archives of pharmacology	doi: 10.1007/s00210-025-04532-x
40928035	2025 Sep 10	Liu Y, Wang X, Krishnan N, Hsiao T, Ji Y, Kaneko K, Teneche MG, Adams PD, Zuniga E, Kaech SM, Zhang L, Feng GS	Efficacious suppression of primary and metastasized liver tumors by polyIC-loaded lipid nanoparticles.	Hepatology (Baltimore, Md.)	doi: 10.1097/HEP.0000000000001514
40927960	2025 Sep	Sakai K, Ishii S, Yokosuka S, Takahashi T, Kawano Y, Nishimura H, Kuwabara Y, Sasaki-Toda M, Ogawa-Kobayashi Y, Kikuchi S, Hirata Y, Kyoyama H, Moriyama G, Koyama N, Uematsu K	Efficacy of Immune Checkpoint Inhibitors in Combination With Platinum-Based Doublet Chemotherapy for Extensive-Stage Small-Cell Lung Cancer Patients With Eastern Cooperative Oncology Group-Performance Status 2-3: A Single-Institution Retrospective Study.	Cancer medicine	doi: 10.1002/cam4.71136
40927723	2025	Alsharif N, Qaisi M, Shaul M, Kaisar-Iluz N, Padawer D, Bouhanna O, Volman Y, Fridlender ZG	Human lung cancer neutrophils generate NETs with preserved anti-tumor cytotoxicity but impaired anti-migratory activity.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1643609
40927719	2025	Peng L, Li H, Yan W, Liu Y, Zhu H, Hong Y	Integrative profiling of lung cancer biomarkers EGFR, ALK, KRAS, and PD-1 with emphasis on nanomaterials-assisted immunomodulation and targeted therapy.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1649445
40927709	2025	Wu D, Ju D, Zhao Y, Liu W, Liu Q, Liang Y	Unraveling epigenetic drivers of immune evasion in gliomas: mechanisms and therapeutic implications.	Frontiers in immunology	doi: 10.3389/fimmu.2025.1633338
